Novonesis A/S (Novozymes A/S)

NSIS B

Equity

ISIN DK0060336014 / Valor 14371062

Nasdaq Copenhagen Equities (2024-12-23)

DKK 408.00+0.79%

Novonesis A/S (Novozymes A/S)
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Novozymes A/S, a global leader in the biotechnology industry, specializes in the development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. With a history dating back to the 1920s, the company has established a significant presence in over 130 markets, serving more than 30 industries with its innovative solutions. Novozymes' product portfolio is diverse, encompassing applications in areas such as agriculture, food and beverages, bioenergy, household care, and pharmaceuticals. The company's commitment to biotechnological research and development has positioned it at the forefront of the biosolutions sector, enabling it to offer advanced protein, enzymatic, and microbial solutions. Through strategic acquisitions and partnerships, Novozymes continues to expand its global footprint and product offerings, aiming to address the evolving needs of its customers and contribute to sustainable industrial processes.

Summarized from source with an LLMView SourceSector: Industrials

Organic Sales Growth

In the first nine months of 2024, Novonesis A/S (Novozymes A/S) achieved a 9% organic pro forma sales growth, with a notable 11% increase in the third quarter. This growth was driven by a 7% rise in volumes and a 2% contribution from pricing. The company's pro forma sales reached EUR 2,964.1 million, marking a 6% increase, despite a 2% negative impact from currency fluctuations and a 1% decrease due to mergers and acquisitions.

Food & Health Biosolutions Performance

Novonesis A/S's Food & Health Biosolutions segment reported an 8% organic pro forma sales growth for the first nine months of 2024, with a strong 11% growth in the third quarter. The segment's pro forma sales amounted to EUR 1,337.1 million, reflecting a 3% increase. The Food & Beverages sub-segment grew by 9% organically, while Human Health saw a 3% increase, aligning with expectations.

Planetary Health Biosolutions Growth

The Planetary Health Biosolutions segment of Novonesis A/S experienced a 9% organic pro forma sales growth in the first nine months of 2024, with a 12% increase in the third quarter. Pro forma sales for this segment were EUR 1,627.0 million, representing an 8% increase. Household Care led the growth with a 15% organic increase, while Agriculture, Energy & Tech grew by 7% organically.

Reported Sales Performance

According to IFRS reporting, Novonesis A/S reported a 9% organic sales growth for the first nine months of 2024. The company's reported sales in EUR were 2,852.1 million, compared to EUR 1,785.1 million in the same period of 2023. This growth reflects the company's strong performance across various segments and regions.

2024 Financial Outlook

For the full year 2024, Novonesis A/S expects organic sales growth to be at the upper end of the 7-8% range, with an adjusted EBITDA margin confirmed between 35.5-36.5%. Both the Food & Health Biosolutions and Planetary Health Biosolutions segments are anticipated to grow at similar levels as the overall group. The company remains optimistic about its growth prospects, supported by strong demand and innovation.

Summarized from source with an LLMView Source

Key figures

10.7%1Y

-21.3%3Y

24.8%5Y

Performance

22.8%1Y

28.2%3Y

27.5%5Y

Volatility